Keyphrases
Helicobacter Pylori Eradication
66%
Endoscopic Features
66%
Magnifying Endoscopy with Narrow-band Imaging
48%
CDH1
40%
Chromoendoscopy
38%
White Light Endoscopy
35%
Hamartomatous Polyposis Syndromes
33%
Human Gastric mucosa
33%
Light Blue Crest
33%
Anti-PD-1 Antibody
33%
Fosaprepitant
33%
Aprepitant
33%
Promoter Polymorphism
33%
Gastric Epithelium
33%
HRH2
33%
Aberrant DNA Methylation
33%
Methylation
33%
Non-neoplastic
33%
Leukocyte DNA
33%
IGF2 DMR
33%
Regorafenib
33%
TAS-116
33%
Oral Inhibitors
33%
Efficacy Predictor
33%
Atezolizumab Plus Bevacizumab
33%
Depressed Lesion
33%
Clinical Pathological Characteristics
33%
Cabozantinib
33%
MBL2 Gene
33%
Innate Immune Response
33%
Stage III Gastric Cancer
33%
β-tubulin Gene
33%
Residual DNA
33%
Second-look Endoscopy
33%
Rs11614913
33%
Pre-microRNA
33%
Blood DNA Methylation
33%
MiR-146a rs2910164
33%
Feasibility Trial
33%
Gastric Cancer Patients
33%
Common Genetic Variants
33%
Inflammatory Myofibroblastic Tumor
33%
Primary Lesion
33%
Esophagus
33%
Well-differentiated Pancreatic Neuroendocrine Tumor
33%
Gastric Cancer
30%
Genotype
29%
CpG Island Methylation
26%
Overall Survival
26%
Homozygote
23%
CC Genotype
20%
Single nucleotide Polymorphism
20%
Gastric Neoplasia
20%
Mannose-binding Lectin
19%
Bile Duct Tumor
16%
CDH1 Methylation
14%
Non-cancer
14%
Sessile Serrated Adenoma
14%
Adenoma Polyp
14%
Interleukin-1 Gene
13%
Diagnostic Reliability
13%
Chromosomal Instability
13%
Advanced Gastrointestinal Stromal Tumor
13%
Post-eradication
13%
Age Groups
13%
MiR-196a
13%
Rs3746444
13%
MiR-146a
13%
Helicobacter Pylori (H. pylori)
12%
Morphological Appearance
11%
Delayed Vomiting
11%
Exophytic
11%
Exophytic Tumor
11%
Adjusted P-value
11%
Pathological Diagnosis
10%
Tumorous
10%
Non-gastric
9%
Atrophy
9%
Metaplasia
9%
Early Gastric Cancer
9%
Juvenile Polyposis Syndrome
8%
Chronic Anemia
8%
White Surface
8%
Patient Informed Consent
8%
Subsequent Chemotherapy
8%
IV Infusion
8%
Tumor Samples
8%
Taxane Resistance
8%
Nucleotide Substitution
8%
Preoperative Diagnosis
8%
Recurrence or Metastasis
8%
Myofibroblast
8%
After Surgery
8%
Cell Infiltration
8%
Old Japanese
8%
No Recurrence
8%
Surgical Resection
8%
Subepithelial Lesion
8%
Dysphagia
8%
Cervical Esophagus
8%
Medicine and Dentistry
Narrow Band Imaging
100%
Endoscopy
75%
Magnifying Endoscopy
70%
Adenoma
68%
Chromoendoscopy
44%
Polyp
41%
Neoplasm
39%
White Light Endoscopy
38%
Stomach Cancer
38%
Pepsinogen
33%
Cholangitis
33%
Omeprazole
33%
Common Bile Duct
33%
Bile Duct
33%
Colorectal Tumor
33%
microRNA
33%
Helicobacter Pylori
33%
Lymphatic Follicle
33%
Image Enhanced Endoscopy
33%
Colorectal Adenoma
33%
Colon Mucosa
33%
Venous Ulcer
33%
Endoscopic Submucosal Dissection
33%
Gastrointestinal Stromal Tumor
33%
Cancer
33%
Esophagus
33%
Plasma Cell Granuloma
33%
Pancreas Islet Cell Tumor
33%
Sunitinib
33%
Cancer Risk
25%
Pylorus
16%
Familial Adenomatous Polyposis
16%
Colon
16%
Symptom
16%
Sensitivity and Specificity
15%
Carcinoma
15%
Surgery
15%
Early Cancer
13%
microRNA 143
13%
Endoscopic Retrograde Cholangiopancreatography
13%
Bile Duct Cancer
13%
Common Bile Duct Stone
13%
Biopsy
13%
Extrahepatic Bile Duct
13%
Intestinal Metaplasia
12%
Rectum Adenoma
12%
Prevalence
12%
Odds Ratio
12%
Malignant Neoplasm
11%
Multivariate Analysis
10%
Morphology
9%
Indigo Carmine
8%
Computer Assisted Tomography
8%
Juvenile Polyposis Syndrome
8%
Plasma Cell
8%
Hyperplasia
8%
Erythema
8%
Ascending Colon
8%
Colonoscopy
8%
Colorectal Cancer
8%
Cecum
8%
Lymphocyte
8%
Food Allergy
8%
Logistic Regression Analysis
8%
Immune Response
8%
Vermiform Appendix
8%
Clinical Pathway
8%
Cellular Infiltration
8%
Blood Cell
8%
Plummer-Vinson Syndrome
8%
Rare Tumor
8%
Myofibroblast
8%
Recurrent Disease
8%
Metastatic Carcinoma
8%
Informed Consent
6%
Magnetic Resonance Cholangiopancreatography
6%
Diagnostic Imaging
6%
Disease
6%
Abdominal Pain
6%
Cholangiography
6%
Endoscopic Sphincterotomy
6%
Epithelial Cell
6%
Cholangiocarcinoma
6%
Capillary Network
6%
Endoscopic Imaging
6%
Comb
6%
Oteracil
6%
Gimeracil
6%
Tegafur
6%
Preoperative Chemotherapy
6%
Bisulfite
5%
Pyrosequencing
5%
Adenocarcinoma
5%
Carmine
5%
Diagnosis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Helicobacter Infection
100%
Adenoma
76%
Stomach Cancer
73%
Lactoferrin
66%
Colorectal Tumor
66%
microRNA
66%
Infection
56%
Malignant Neoplasm
50%
Helicobacter Pylori
48%
Neoplasm
47%
Colorectal Adenoma
43%
Bevacizumab
40%
Gastric Mucosa
40%
Inflammation
33%
Imatinib
33%
Gastrointestinal Stromal Tumor
33%
Meglumine
33%
Aprepitant
33%
Adverse Event
33%
Fosaprepitant
33%
Intestine Tumor
33%
Placebo
33%
Chemotherapy
33%
Alpha Fetoprotein
33%
Liver Cell Carcinoma
33%
Regorafenib
33%
Delirium
33%
Feces microflora
33%
Atezolizumab
33%
Cabozantinib
33%
Disease
29%
microRNA 143
20%
Overall Survival
18%
Rectum Adenoma
18%
Adenocarcinoma
17%
Familial Adenomatous Polyposis
16%
Carcinoma
16%
Immune Checkpoint Inhibitor
15%
Omeprazole
14%
Polyp
13%
Early Cancer
13%
Disease Exacerbation
13%
Gastritis
12%
microRNA 145
11%
Atrophic Gastritis
8%
Ascending Colon
8%
Symptom
8%
Colorectal Cancer
8%
Erythema
8%
Prevalence
8%
Hyperplasia
8%
Food Allergy
8%
Prothrombin
7%
Progression Free Survival
7%
Liver Metastasis
6%
Cisplatin
6%
Capecitabine
6%
Fluorouracil
6%
Carminic Acid
6%
Indigo Carmine
6%
Interleukin 8
6%
Ammonium
6%
Anticarcinogen
5%
Drug Resistance
5%
Colorectal Carcinoma
5%
microRNA 34a
5%
microRNA 31
5%
Recurrent Disease
5%
Tegafur
5%
Gimeracil
5%
Oteracil
5%